The mission of IQ Corporation is to become an important player on the international market for products relating to flow cytometry and transplantation immunology. Another important activity is the development of innovative tumor treatment using monoclonal antibodies.

These goals will be achieved by strategic research & innovative development of new products in collaboration with a our worldwide network of distributors, as well by developing strategic partnerships or participation's in new or existing companies.

History:
IQ Corporation was originally founded in 1987 as a spin-off from the University of Groningen and the University Hospital Groningen, The Netherlands. In 1990 the company was restructured. The current management dates from that time.

Key personnel:
Dr. Roland G. Lageveen, General Manager; Drs. Martinus W.A. de Jonge, Research & Development Manager; Harry Aaldenberg, Marketing & Sales Manager

Employees:
At the moment IQ Corporation employs 20 full time employees, among which 3 PhD's, 6 technicians and 3 marketing. Moreover the company supports 2 full time research employees at the University of Groningen.

Marketing & sales:
IQ Products is a 100% subsidiary of IQ Corporation, focusing on the worldwide marketing & sales of products for flow cytometry, CMV diagnosis, immunohistochemistry.

IQ Products has established a worldwide network of distributors covering all important markets for human health care.

R & D focus:
Research is carried out in close cooperation with universities in the Netherlands and the USA, as well as with other companies.

R & D activities focus on the following areas:

• immune-reagents and diagnostics for applcation in flow cytometry
• immunity and diagnosis of Cytomegalovirus (CMV) infection and transplant related diagnostics
• development of rapid antibody-based tests
• in vivo applications of monoclonal antibodies (imaging and therapy) aiming at innovative treatment of tumors